CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Status:
Recruiting
Trial end date:
2023-09-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351)
works in treating patients with secondary acute myeloid leukemia who are younger than 60
years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading.